Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Baraldi

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 10, 2022
The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraineSimona Guerzoni, Carlo Baraldi, Luca Pani
Expert Opinion on Investigational Drugs|October 21, 2017
Glutamate receptor antagonists with the potential for migraine treatmentAnna Ferrari, Cecilia Rustichelli, Carlo Baraldi
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2015
Medication overuse and chronic migraine: a critical review according to clinical pharmacologyAnna Ferrari, Carlo Baraldi, Emilio Sternieri
Clinical Drug Investigation|March 23, 2025
Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic ReviewIbrahim Hajjaj, Carlo Baraldi, Lanfranco Pellesi
CNS Drugs|May 13, 2018
Polypharmacy Among Headache Patients: A Cross-Sectional StudyAnna Ferrari, Carlo Baraldi, Manuela Licata, et al.
Expert Opinion on Drug Discovery|June 10, 2024
The preclinical discovery and development of atogepant for migraine prophylaxisCarlo Baraldi, Dagmar Beier, Paolo Martelletti, et al.
Journal of Clinical Medicine|March 25, 2022
Clinical Evidence of Cannabinoids in Migraine: A Narrative ReviewFlavia Lo Castro, Carlo Baraldi, Lanfranco Pellesi, et al.
Expert Opinion on Investigational Drugs|September 3, 2020
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief reviewCecilia Rustichelli, Flavia Lo Castro, Carlo Baraldi, et al.
The Journal of Headache and Pain|May 6, 2016
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatmentSimona Guerzoni, Lanfranco Pellesi, Carlo Baraldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2023
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life studySimona Guerzoni, Flavia Lo Castro, Daria Brovia, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 10, 2022
The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraineSimona Guerzoni, Carlo Baraldi, Luca Pani
Expert Opinion on Investigational Drugs|October 21, 2017
Glutamate receptor antagonists with the potential for migraine treatmentAnna Ferrari, Cecilia Rustichelli, Carlo Baraldi
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2015
Medication overuse and chronic migraine: a critical review according to clinical pharmacologyAnna Ferrari, Carlo Baraldi, Emilio Sternieri
Clinical Drug Investigation|March 23, 2025
Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic ReviewIbrahim Hajjaj, Carlo Baraldi, Lanfranco Pellesi
CNS Drugs|May 13, 2018
Polypharmacy Among Headache Patients: A Cross-Sectional StudyAnna Ferrari, Carlo Baraldi, Manuela Licata, et al.
Expert Opinion on Drug Discovery|June 10, 2024
The preclinical discovery and development of atogepant for migraine prophylaxisCarlo Baraldi, Dagmar Beier, Paolo Martelletti, et al.
Journal of Clinical Medicine|March 25, 2022
Clinical Evidence of Cannabinoids in Migraine: A Narrative ReviewFlavia Lo Castro, Carlo Baraldi, Lanfranco Pellesi, et al.
Expert Opinion on Investigational Drugs|September 3, 2020
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief reviewCecilia Rustichelli, Flavia Lo Castro, Carlo Baraldi, et al.
The Journal of Headache and Pain|May 6, 2016
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatmentSimona Guerzoni, Lanfranco Pellesi, Carlo Baraldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2023
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life studySimona Guerzoni, Flavia Lo Castro, Daria Brovia, et al.
Pageof 6